Mirae Asset Global ETFs Holdings’s Recursion Pharmaceuticals RXRX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.62M	Buy	441,931 +47,302	+12%	+$157K	﹤0.01%	1366
2026 Q1	$1.2M	Sell	394,629 -1,635	-0.4%	-$6.32K	﹤0.01%	1434
2025 Q4	$1.62M	Buy	396,264 +187,504	+90%	+$929K	﹤0.01%	1259
2025 Q3	$1.02M	Buy	208,760 +5,266	+3%	+$27.7K	﹤0.01%	1480
2025 Q2	$1.03M	Buy	203,494 +26,060	+15%	+$128K	﹤0.01%	1432
2025 Q1	$953K	Buy	177,434 +12,372	+7%	+$90.2K	﹤0.01%	1529
2024 Q4	$1.12M	Buy	165,062 +7,939	+5%	+$53.4K	﹤0.01%	1490
2024 Q3	$1.05M	Buy	157,123 +72,182	+85%	+$517K	﹤0.01%	1516
2024 Q2	$638K	Buy	+84,941	New	+$741K	﹤0.01%	1702

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's RXRX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Recursion Pharmaceuticals (RXRX) stake by 12% in Q2 2026, buying an estimated $157K and bringing the position to 441,931 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

Mirae Asset Global ETFs Holdings first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Mirae Asset Global ETFs Holdings held 441,931 shares of Recursion Pharmaceuticals worth $1.62M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 47,302 Recursion Pharmaceuticals shares in Q2 2026, an estimated $157K.
Recursion Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1366 holding.
Mirae Asset Global ETFs Holdings first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.